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A physiological function of the original uncoupling protein, UCP1, is well established: UCP1 is the molecular background for nonshivering
thermogenesis. The functions of the “novel” UCPs, UCP2 and UCP3, are still not established. Recent discussions imply that all UCPs may play a
role in protection against reactive oxygen species (ROS). Here we examine critically the evidence that UCP1, UCP2 and UCP3 are stimulated by
ROS (superoxide) or ROS products (4-hydroxy-2-nonenal), and that the UCPs actually diminish oxidative damage. We conclude that, concerning
UCP1, it is unlikely that it has such a role; concerning UCP2/UCP3, most evidence for physiologically significant roles in this respect is still
circumstantial.
© 2006 Elsevier B.V. All rights reserved.The realization that the mammalian genome contains not only
the gene for the original uncoupling protein UCP1 but a small
family of genes (UCP1, UCP2, UCP3) [1] that together
constitute an “uncoupling-protein-like” subfamily within the
family of mitochondrial carrier proteins has left the scientific
community with the enigma of the physiological function(s) of
the novel uncoupling proteins (UCP2, UCP3). Nearly a decade
after their first identification, no generally accepted role for the
novel UCPs exists (although many roles have been discussed
(reviewed in [2]). Particularly, the suggestion that they may be
involved in the defence against reactive oxygen species (ROS)
and in this way prevent or ameliorate oxidative damage has
attracted and continues to attract much attention (see, e.g., [3]).
This possibility was first formulated in a very early but
influential paper by Nègre-Salvayre et al. [4] which combined
the largely accepted view that a high mitochondrial membrane
potential leads to increased production of ROS (particularly
superoxide) with the idea (at that time accepted by most
researchers) that UCP2 was really a functional uncoupling
protein, and thus formulated that the presence of UCP2 could
protect against ROS production. This suggestion was extended
by Brand and colleagues who proposed that UCP activity was
regulated by superoxide [5] or ROS products [6]. In this way a⁎ Corresponding author.
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doi:10.1016/j.bbabio.2006.05.016coherent theory for a feed-back mechanism was formulated
where an increased ROS production would activate a mecha-
nism (uncoupling) that would decrease ROS formation, and
oxidative damage would thereby be reduced. This formulation
has attracted much general interest due to the possibility that
oxidative damage may be causative of many health problems,
including cancer and ageing. We discuss this issue here, with
emphasis on studies of the original uncoupling protein, UCP1.
The discussion can be subdivided into several issues: do ROS or
ROS products activate (any) uncoupling proteins, do any of the
uncoupling proteins protect against oxidative damage, and is
there a functional link, particularly in-vivo, between uncoupling
and protection against oxidative damage?
1. Do ROS or ROS products activate uncoupling proteins?
As knowledge of – and known characteristics of – the three
different uncoupling proteins are quite dissimilar, it is
advantageous to discuss the issues for each uncoupling protein
separately, starting with the nomenclative uncoupling protein,
UCP1.
1.1. Is UCP1 activity affected by ROS or ROS products?
UCP1 is only found in brown adipose tissue [7]; reports on
expression elsewhere (smooth muscle [8], thymus [9]) have to
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state conditions, the amount of UCP1 protein displays a simple
relationship to UCP1 mRNA levels [10], and the amount of
UCP1 in brown-fat mitochondria is high, up to 10% of the
mitochondrial membrane protein [11]. UCP1 is both fully
responsible for – and indispensible for – the phenomenon of
classical nonshivering thermogenesis [12], i.e., the extra heat
production that develops in mammals as an effect of acclimation
to cold, in order to replace shivering (which is the acute defence
against cold) with a more “comfortable” heat-producing
process. Whether UCP1 also has a role (obligatory, optional
or addition) in the metabolic adaptation to different diets (so-
called diet-induced thermogenesis) is still not established [7].
1.1.1. Fatty acids in UCP1 function
There are basically two schools concerning the functional
mechanism of UCP1 (reviewed in more detail in [13]). One
group who have mainly examined UCP1 in reconstituted
systems (liposomes) maintain that fatty acids are necessary for
UCP1 function; the other group, working with UCP1 in its
native environment, i.e., in brown fat mitochondria, maintain
that fatty acids are not necessary for function, i.e., that UCP1 is
innately active in isolated brown-fat mitochondria. The main
argument against fatty-acid-independent innate activity is that it
cannot be excluded that some fatty acids are always present in
the mitochondrial membranes. The main argument against the
necessity for fatty acids for function is that this necessity is only
obvious when UCP1 activity is examined in reconstituted
systems. This may imply that in reconstituted systems the
protein is not in its native state, as it is, e.g., not exposed to the
strong membrane potential under which it is normally working.
Indeed, we find that a proton leak associated with UCP1 can
only be observed at membrane potentials more polarized than
−120 mV [14].
1.1.2. Inhibition by GDP
There is, however, general agreement that GDP and other
purine nucleotides (GTP, ADP and ATP) inhibit UCP1 function.
In extrapolation of this, UCP1 is expected to be in an inhibited
state within the brown-fat cells, due to inhibition by cytosolic
nucleotides (mainly ATP). There is thus a functional require-
ment for a UCP1 reactivator, i.e., a compound/process that can
overcome this inhibition when thermogenesis is needed.
Irrespective of the question of whether fatty acids are necessary
for UCP1 function (proton transport), there is fairly good
agreement that, physiologically and experimentally, fatty acids
“overcome” the inhibition caused by nucleotides. We have
found that fatty acids do this in a kinetically simple competitive
manner [15]. However, the issue is probably more complex, as
there is no demonstration of a high-affinity competition
between fatty acid and GDP for the nucleotide-binding site on
UCP1. In a characterization of the properties that are necessary
for the re-activation of GDP-inhibited UCP1 we found that a
very broad spectrum of fatty acids could do this, including so-
called non-flip-flopping fatty acids (see also [16]). We also
observed that there was a principal difference between flip-
flopping and non-flip-flopping fatty acids, not in their ability tore-activate UCP1, but in their ability to mediate UCP1-
independent proton leak [17,18]: non-flip-flopping fatty acids
were unable to “uncouple” in a UCP1-independent way.
1.1.3. Activation by superoxide?
Originally based on observations of an apparent require-
ment for coenzyme Q for successful reconstitution of UCP1
activity in liposomes [19] (which is probably not physiolog-
ically relevant [20]), the hypothesis was formulated that ROS
(or ROS products) activate UCP1 [5] and may be necessary
for UCP1 function. We have had the opportunity to examine
this interesting hypothesis in an in-vivo system. Human
mitochondrial superoxide dismutase was expressed in mice
under its own promoter, assuring physiological levels of
expression. In the transgenic mice, the human superoxide
dismutase was expressed at different levels in different tissues,
including brown adipose tissue. This led to a somewhat (but
not drastically) increased total superoxide dismutase activity,
and the increased activity resulted in a lower release of
superoxide from isolated brown-fat mitochondria [21].
Notably, aconitase activity was enhanced in brown-fat
mitochondria isolated from such mice, indicating both that a
superoxide inhibition of aconitase takes place in-vivo and that
in this context there is a physiologically significant effect of
the increased superoxide dismutase activity. Thus, there is
good reason to think that the overexpression is not only
demonstrable in an isolated system but also affects superoxide
levels in-vivo. These transgenic mice may therefore be
considered a rewarding system to use to examine the ability
of superoxide to control UCP1 function.
In isolated brown-fat mitochondria from these superoxide
dismutase-overexpressing mice, we have investigated maximal
UCP1 activity. We have also examined the inhibitory effect of
GDP and the ability of fatty acids to overcome the inhibition of
UCP1 activity caused by GDP. We did not find that this
moderate overexpression of superoxide dismutase affected any
of these parameters [21], implying that alteration of superoxide
levels could not influence UCP1 function.
However, all of these observations were performed in an
isolated system (isolated brown-fat mitochondria) and it may be
commented that this may not reflect true regulation in-vivo.
Therefore, to examine the superoxide hypothesis in-vivo, we
utilized the fact that the activity of UCP1 is reflected in the
intact animal in the form of a metabolic response to
norepinephrine injection (increased oxygen consumption).
Particularly, it is known that the entire increase in response to
norepinephrine that is observable as an effect of cold
acclimation of mice (which results in a recruitment of brown
adipose tissue, including a vast increase in the amount of UCP1)
is due to UCP1 activity [22]. If the decreased levels of
superoxide caused by the overexpression of superoxide
dismutase would lead to reduced activity of UCP1 in-situ, we
would expect a much lower response to norepinephrine
injection in the superoxide-overexpressing mice. However, we
found that the response was exactly the same in control as in
superoxide dismutase-overexpressing mice. Thus, we could
neither find support in an isolated system (brown-fat
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superoxide directly or indirectly regulates UCP1 activity.
1.1.4. Activation by 4-hydroxy-2-nonenal?
In the current formulations of the superoxide hypothesis, it
is not superoxide as such but rather compounds such as 4-
hydroxy-2-nonenal that are responsible for the direct activation
of UCP1 [6]. The 4-hydroxy-2-nonenal is believed to be
formed by superoxide products interacting with polyunsaturat-
ed fatty acids in the phospholipids of the mitochondrial
membrane. Based on this formulation, we have also investi-
gated the ability of 4-hydroxy-2-nonenal to activate UCP1. In
these investigations, we have utilized brown-fat mitochondria
from wild-type mice, as well as from UCP1-ablated mice, to
enable us to distinguish between UCP1-dependent and UCP1-
independent effects of 4-hydroxy-2-nonenal. In brown fat
mitochondria from UCP1-ablated mice, there was no “uncou-
pling” effect of 4-hydroxy-2-nonenal, and even in brown fat
mitochondria from wild-type mice in which the UCP1 activity
was inhibited with GDP, there was no effect of 4-hydroxy-2-
nonenal; 4-hydroxy-2-nonenal was thus unable to re-activate
GDP-inhibited UCP1 (in contrast to fatty acids). This, of
course, makes it difficult to understand how 4-hydroxy-2-
nonenal could activate UCP1 within the cell, i.e., could
overcome the ATP inhibition there. We also found that 4-
hydroxy-2-nonenal was unable to affect the activity of
uninhibited UCP1 at any membrane potential where UCP1 is
active (i.e., at membrane potentials more polarized than −120
mV) [14].
If 4-hydroxy-2-nonenal activates UCP1, it could do this
either non-covalently or covalently. If it activates covalently, it
should be possible to observe hydroxynonenal adducts to
UCP1. When isolated brown-fat mitochondria are incubated
with hydroxynonenal and the formation of different protein/
hydroxynonenal adducts followed, we find no adduct
corresponding to UCP1, despite the high amount of UCP1 in
the brown-fat mitochondria. Also in brown-fat mitochondria
isolated from physiologically highly active brown adipose
tissue we were unable to observe hydroxynonenal/UCP1
adducts [14]. This also speaks against the possibility that
UCP1 could be “pre-activated” by 4-hydroxy-2-nonenal prior
to mitochondrial isolation and that this could be the reason that
we failed to see an activating effect of 4-hydroxy-2-nonenal in-
vitro.
1.1.5. Alternative actions of 4-hydroxy-2-nonenal
(and superoxide)
Although we were unable to observe any 4-hydroxy-2-
nonenal-induced activation of UCP1, we did observe an
increased proton leak due to 4-hydroxy-2-nonenal treatment
of brown-fat mitochondria (but this leak was identical whether
UCP1 was present or not). Thus: if 4-hydroxy-2-nonenal does
not activate UCP1— what is then the explanation for the effect
of 4-hydroxy-2-nonenal on brown-fat mitochondria (i.e., the
increased proton leak) observed both by Echtay and colleagues
[6] and by us [14]? There is the possibility that it could be due to
activation of UCP2 or UCP3, provided that these proteins aretruly activated by 4-hydroxy-2-nonenal (we discuss the
evidence for this below).
However, we would especially like to point to the so-called
mitochondrial permeability transition pore, the nature of which
remains obscure (especially as earlier, apparently well-estab-
lished views concerning its nature have become challenged by
(lack-of) effects of gene ablation of these suggested proteins
[23]). Indeed, the possibility that a fraction of the effect of 4-
hydroxy-2-nonenal on brown-fat mitochondria could be
mediated by the permeability transition pore was already
discussed by Echtay et al. [6] who found that both carboxya-
tractylate (supposedly inhibiting the adenine nucleotide translo-
case presumed to form the permeability transition pore) and
GDP (presumably inhibiting UCP1) inhibited the 4-hydroxy-2-
nonenal-induced proton leak—but in a non-additive way. This
non-additivity is difficult to reconcile with GDP and carbox-
yatractylate interacting with different proteins. There is some
literature evidence that GDP may interact with (although not be
transported by) the adenine nucleotide translocase [24,25,71]. A
(so far untested) hypothesis may therefore be forwarded that
both carboxyatractylate and GDP inhibit the 4-hydroxy-2-
nonenal-induced permeability transition pore, and it is the 4-
hydroxy-2-nonenal-induced permeability transition pore that is
responsible for the 4-hydroxy-2-nonenal effects on brown-fat
mitochondria. Indeed, 4-hydroxy-2-nonenal is well known to be
able to induce the pore in other mitochondria types [26], and we
have confirmed that incubation of UCP1-KO brown-fat
mitochondria with hydroxynonenal does induce a time-
dependent decrease in membrane potential. It can thus be
understood that such a mechanism could explain the GDP-
sensitive 4-hydroxy-2-nonenal-induced proton leak not only in
the UCP1-KO brown-fat mitochondria but also in some other
mitochondria types, as well as the GDP-sensitive superoxide-
induced proton leak observed in brown-fat mitochondria [5].
1.1.6. Conclusion concerning UCP1
The above data imply that UCP1 activity is not regulated by
ROS or ROS products. While this indicates that ROS regulation
of activity is not a general feature of members of the uncoupling
protein family, it does not contradict the possibility that the
other family members, UCP2 and UCP3, may display ROS-
regulated activity.
1.2. Is UCP2 activity affected by ROS or ROS products?
Although UCP2 – which is expressed in many tissues – is
undoubtedly phylogenetically a member of the uncoupling
protein family [27], its status as a functional uncoupling protein
is much doubted. Earlier observations of apparent inherent
uncoupling function of UCP2 are now suggested to have been
artefacts of the experimental systems used [28]. Indeed, there is
no observable proton leak ascribable to UCP2 when mitochon-
dria from UCP2-expressing tissues (lung, spleen) are examined
[29] (i.e., the proton leak is the same in wild-type and UCP2
knockout mice). There may be several explanations for this: the
amount of UCP2 may be so low that its uncoupling activity is
not detectable (which would make it difficult to ascribe a
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be an uncoupling protein or, in contrast to UCP1, it may need
activation in-vitro to display its uncoupling properties.
1.2.1. UCP2 amounts
Although UCP2 is well expressed in many tissues at the
mRNA level, it would seem that the protein level of UCP2 is not
simply proportional to the mRNA level, and UCP2 protein is
apparently undetectable in several tissues where UCP2 mRNA
is easily observable [30]. The reason for the discrepancy
between UCP2 mRNA levels and UCP2 protein levels is not
known but may be related to the existence in the 5′ non-coding
region of the mRNA of another open reading frame. This open
reading frame corresponds theoretically to a 36 amino acid
peptide which is highly conserved between species [31].
However, whether this protein is ever formed has not been
reported, although deletion of this open reading frame indeed
increases UCP2 translation [30]. The point remains that the
amounts of UCP2 present in mitochondria are at least two
orders of magnitude lower than the amount of UCP1 in brown-
fat mitochondria, even in those mitochondria with the highest
UCP2 protein levels [30]. As the ROS-induced proton leaks
ascribed to UCP1 in brown-fat mitochondria and to UCP2 in
mitochondria from certain other tissues (see below) are
approximately equal in magnitude, the only explanation
would be that UCP2 has an uncoupling activity two orders of
magnitude higher than that of UCP1, a property that would not
seem very likely.
1.2.2. UCP2 activation by superoxide?
The possibility that UCP2 is an uncoupling protein but that it
needs an activating factor was first implied by experiments of
Echtay et al. [5]. Utilizing an exogenous system for generation
of superoxide (xanthine plus xanthine oxidase), they found that
they could demonstrate an increased proton leak in mitochon-
dria from certain tissues, apparently being UCP2-expressing
tissues, and that this superoxide-induced proton leak could be
inhibited by GDP, and they thus concluded that superoxide
activated an uncoupling function of UCP2. However, the
validity of these observations has later been discussed.
A technical argument has been forwarded by Couplan et al.
[29]. These authors argue that the method for producing
superoxide (xanthine plus xanthine oxidase) in itself utilizes
oxygen and that this oxygen utilization results in an apparently
higher oxygen utilization at any given membrane potential,
giving the impression of an increased proton leak. When the
extra oxygen utilization was compensated for, no increased
proton leak was observable. Echtay et al. [32] have in their turn
performed similar calculations and maintain that there is a
genuine superoxide-induced proton leak.
The superoxide-induced proton leak correlates with UCP2
expression in the way that it is not observed in liver
mitochondria (that lack UCP2) but is observed in spleen
mitochondria (that contain UCP2) [5]. However, two further
observations make this correlation debatable: one is that no
superoxide activation of heart mitochondria is seen—this is not
strange in that heart does not contain UCP2 but is strangebecause heart contains UCP3 (see below). The second concerns
kidney mitochondria, where a superoxide effect was seen [5].
However, although kidney expresses UCP2 at the mRNA level,
Pecqueur et al. [30] have been unable to observe UCP2 protein
in kidney, apparently making it impossible that UCP2 could be
the mediator of the superoxide effect. Against this stands that
Lowell's group not only observed UCP2 protein in the kidney
but also demonstrated that the effect of exogenously generated
superoxide in kidney mitochondria disappeared in UCP2 KO
mouse [33].
In the mice that overexpress superoxide dismutase, we have
also attempted to investigate whether the decreased levels of
superoxide would affect UCP2 function. However, the choice of
tissue from which to isolate the mitochondria is difficult. This is
because, as indicated above, many tissues where UCP2 mRNA
is found do not contain detectable levels of UCP2 protein [30].
The tissue with the mitochondria with the highest protein
expression is the spleen, but—as atated—even here the UCP2
level is 100-fold lower than the UCP1 level in brown-fat
mitochondria [30], and spleen mitochondria are not easy to
work with. We tested brain mitochondria but it can be argued
that UCP2 protein is not found globally in the brain [30]; we
found no indications that increased superoxide dismutase
altered brain mitochondrial parameters [21].
However, we reasoned that if UCP2 activity in any tissue in
the body is regulated by superoxide, and if UCP2 activity
represents an ongoing uncoupling, then total body energy
metabolism (i.e., basal metabolic rate) should be lower in the
mice overexpressing superoxide dismutase. This was, however,
not the case [21]. While this does not exclude the possibility that
in a given tissue, under certain conditions, superoxide could
activate UCP2, nor that this could occur constantly in a
metabolically minor tissue in the body, this observation would
seem to preclude that this process is a generally ongoing
mechanism in large parts of the body.
A further argument that the superoxide-induced proton leak
is really through UCP2 is that it is inhibitable by GDP. It would
not be unexpected that GDP could inhibit UCP2 activity, as the
amino acids with which GDP interacts in UCP1 are fully
conserved in all UCPs (and this is specific for UCPs versus
other members of the mitochondrial carrier family (compiled in
[13])). It has also been demonstrated that GDP can inhibit UCP2
activity when UCP2 is incorporated into liposomes [34].
However, the possibility still remains that a GDP effect also
exists for other proteins in the mitochondrial membrane (see
Section 1.1.5).
1.2.3. UCP2 activation by 4-hydroxy-2-nonenal
In current formulations, the superoxide effect on UCP2 is
indirect (cf. UCP1 above), mediated via the formation of 4-
hydroxy-2-nonenal and similar compounds [35]. Again, 4-
hydroxy-2-nonenal induces an increased GDP-sensitive proton
leak in certain mitochondria (rat kidney) but the induced proton
leak is not GDP-sensitive in other tissues (liver, heart).
Although this perhaps correlates with UCP2 presence or
absence, more definitive experiments, i.e., experiments with
UCP2 KO animals, have as yet not been performed.
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UCP2 would seem stronger than that for UCP1, a general
acceptance of the phenomenon will have to await the
publication of more conclusive experiments.
1.3. Is UCP3 activity affected by ROS or ROS products?
The third member of the uncoupling protein family, UCP3,
is expressed at the mRNA level only in muscle (including
heart) and brown adipose tissue, and its presence has been
confirmed at the protein level in muscle [36], heart [37] and
brown adipose tissue [38]. Again, early observations that
UCP3 is inherently uncoupling are now ascribed to experi-
mental artefacts [39]. Thus, there is presently no indication
that UCP3 is a functionally inherent uncoupling protein, in
that there is no difference in proton leak between muscle
mitochondria isolated from wild-type and UCP3 KO animals
[40]. Concordantly, increased levels of endogenously
expressed UCP3 do not lead to any signs of “innate
uncoupling” (increased proton leak) [41–43]. Also here the
possibility exists that an in-vitro uncoupling activity could
need an activator to be observable.
1.3.1. Superoxide activation of UCP3?
In muscle mitochondria, artificially generated superoxide
induces an increased proton leak that is GDP sensitive, while no
induced proton leak is observable in muscle mitochondria from
UCP3-ablated mice [5]. It is, however, somewhat unexpected
that heart mitochondria also lack a response to superoxide [5],
considering that they also contain UCP3.
Several studies have investigated whether a physiologically
increased level of UCP3 would lead to a (increased) response to
endogenously generated superoxide. However, in thyroid
hormone-treated rats [44], in LPS-treated animals [45] and in
UCP1-ablated mice [43] (all demonstrating increased UCP3
levels) tested under conditions of high endogenous superoxide
production, no effect was seen on proton conductance,
compared to controls. Similarly, UCP3 overexpression in
CHO cells did not induce any uncoupling activity during
prolonged exposure to oligomycin and to superoxide generated
by mitochondria under these conditions [46].
Correspondingly, in muscle mitochondria from mice over-
expressing superoxide dismutase, we have attempted to
investigate whether the decreased superoxide levels (which
we observe in these mitochondria, both by direct measurements
of superoxide release and by increased aconitase activity)
influence UCP3 activity. We were unable to observe any
difference in fatty acid-induced respiration (“uncoupling”)
between normal mice and superoxide dismutase-overexpressing
mice, and GDP did not have any inhibitory effect on fatty acid-
induced respiration [21]. These experiments thus imply that
endogenously generated superoxide does not have a regulatory
role for UCP3 “uncoupling” activity.
1.3.2. 4-Hydroxy-2-nonenal activation of UCP3?
The issue of stimulation of UCP3 by ROS or a ROS product
is not clarified when the effects of 4-hydroxy-2-nonenal areexamined [6]. As the basic hypothesis is that superoxide exerts
its effects not directly on UCP3 but through the formation of 4-
hydroxy-2-nonenal [47], it would be expected that the responses
to 4-hydroxy-2-nonenal should be identical to those of
superoxide; however, this is not fully the case. Concerning
heart mitochondria, where superoxide itself had no effect, 4-
hydroxy-2-nonenal had an effect, although this effect was not
inhibitable by GDP, but by carboxyatractylate or bongkrekate,
indicating that it was mediated by the adenine nucleotide
translocase and not by the UCP3 present in these mitochondria.
Does this indicate that in heart UCP3 is nonstimulatable by
superoxide/4-hydroxy-2-nonenal? Or does it indicate that
specifically in heart tissue, increased superoxide does not lead
to 4-hydroxy-2-nonenal formation? Similarly, the effect of 4-
hydroxy-2-nonenal has been examined in muscle mitochondria
from UCP3 KO mice, but the results presented are somewhat
complex: in wild-type muscle mitochondria, 4-hydroxy-2-
nonenal induced a proton leak that was fully GDP-sensitive;
in UCP3 KO mice, there was still a 4-hydroxy-2-nonenal-
induced proton leak—but it was GDP-insensitive [6]. When this
information is viewed together with the superoxide data above
(i.e., that superoxide induces a proton leak in wild-type muscle
mitochondria but not in UCP3-KO muscle mitochondria), the
apparent conclusion becomes intricate: does superoxide form 4-
hydroxy-2-nonenal in muscle from wild-type mice but not in
muscle mitochondria from UCP3-KO mice?
Thus, it is not simple to conclude as to whether exogenously
generated ROS or ROS products induce a proton leak fully,
partly or not at all through UCP3 (as compared to through the
adenine nucleotide translocase specifically or through the
permeability transition pore in a broader sense). However, the
absence of effect of superoxide dismutase overexpression [21]
makes it less likely that endogenously generated superoxide
plays a regulatory role for UCP3 function.
1.4. Conclusion concerning ROS activation of UCPs
Although it is irrefutable that there are effects of ROS
(superoxide) and ROS products (4-hydroxy-2-nonenal) on
proton leak in different types of mitochondria, it is difficult to
ascertain whether the effects are mediated through UCPs or in
other ways. Particularly concerning UCP1, available evidence
would not seem to favour a regulatory role for ROS or ROS
products. The difficulties in delineating which of the effects that
are due to activation of, e.g., the mitochondrial permeability
transition pore versus activation of the other UCPs (UCP2 and
UCP3) make it difficult to ascribe effects to one or the other.
Thus, although ROS (product) regulation of UCP activity is an
appealing hypothesis, its validity has as yet not been irrefutably
demonstrated.
2. Do uncoupling proteins protect against oxidative
damage?
Although we concluded above that there is as yet not
irrefutable evidence that UCP1, UCP2 or UCP3 are activated by
ROS or ROS products, this does not exclude the possibility that
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or another, unknown way. To discuss this issue, connections
between UCP presence and activity on the one hand and
oxidative damage on the other have to be established. It is
important that it is the endogenous level of oxidative damage
that is examined in this context.
Although oxidative damage is a much discussed issue in
many areas of biology and medicine, it is a problem that
generally accepted, good parameters for oxidative damage,
reflecting in-situ conditions, are not easily available. The much
used malonyl dialdehyde (MDA) method is difficult to evaluate
in this respect, as it can be said to examine incubation
conditions rather than to reflect the innate situation in the
tissue – or to measure protection by incubation conditions from
experimentally induced ROS production. The formation of 8-
hydroxy-2′-deoxyguanosine – with its connection to carcino-
genesis, etc. – has not been studied in connection with UCP
activity. Aconitase activity is an interesting measure but even
here it may be difficult to distinguish between whether aconitase
activity reflects the situation in-vivo or whether the acute
incubation conditions affect aconitase activity. We have used
the formation of 4-hydroxy-2-nonenal/protein adducts as a
measure of in-situ oxidative damage [14]. We think that this has
the advantage of being a stable indicator that survives isolation
of tissues and for which the risk of alterations caused by the
isolation manipulations is minimal.
2.1. Does UCP1 protect against oxidative damage?
The availability of mice in which the UCP1 gene has been
ablated [48] has given us the possibility to examine whether the
presence of UCP1 protects against oxidative damage in brown
adipose tissue. We have examined the amount of nonenal/
protein adducts in brown-fat mitochondria isolated from these
two types of mice. Although nonenal adducts were observable
in a broad spectrum of proteins with different molecular
weights, we found no indication that the presence or absence of
UCP1 altered the total amount, or the pattern, of nonenal
adducts in the mitochondrial proteins [14]. Although this most
probably indicates the absence of a protective role of UCP1 in
oxidative damage, there may be more complex explanations for
the lack of an effect of the absence of UCP1. There could be a
compensatory increase in the capacity of antioxidative systems,
although those antioxidative enzymes examined did not show
an increased activity [14], or the total capacity of antioxidative
enzymes in brown adipose tissue could be so high that it
overshadowed the effect of UCP1 (but, of course, this would
still mean that UCP1 does not have a physiologically significant
protective role). Thus, it seems most likely that UCP1 as such
does not protect against oxidative damage in brown adipose
tissue.
2.2. Does UCP2 protect against oxidative damage?
The implication that uncoupling proteins protect against
oxidative damage (ROS production) originates from the
observation by Nègre-Salvayre et al. [4] that macrophagemitochondria – as well as spleen and thymus mitochondria –
demonstrated GDP-augmented H2O2 production whereas
mitochondria from hepatocytes did not respond to GDP. The
implication, based both on the GDP effect and the tissue pattern,
was that it was an inhibition of UCP2 activity that was
responsible for the augmented H2O2 production. These very
interesting observations have not been repeated with UCP2 KO
mice so the association is still not verified (although isolated
spleen mitochondria from UCP2 KO mice do produce more
hydrogen peroxide than do wild-type but a response to GDP
was not tested [49]). It may especially be pointed out that the
observations of Nègre-Salvayre et al. must be considered more
surprising now than they were in 1997, because at that time it
was generally believed that UCP2 was inherently uncoupling,
and the augmentation of H2O2 production could thus be
understood as an effect of the increase in membrane potential
caused by GDP-inhibition of this uncoupling. As it is today
generally accepted that UCP2 is not inherently uncoupling,
there is no mechanistic explanation for the observations by
Nègre-Salvayre et al. Indeed, there is no difference between the
proton leak observed in, e.g., spleen mitochondria from wild-
type and UCP2-KO mice [29]; there is therefore, at least in not
activated spleen mitochondria, no UCP2-mediated proton leak
that can be inhibited by GDP.
Apart from this study, the arguments for a protective role are
mainly that the level of UCP2 mRNA is increased in tissues
under conditions of what is referred to as “oxidative stress”; this
includes, e.g., in lung upon LPS treatment and in stomach upon
fasting [30]. However, these conditions are associated with
macrophage invasion. As macrophages contain high amounts of
UCP2, there is the possibility that the increase in the tissue
represents UCP2 from macrophages; indeed both processes
seem to take place [72]. However, irrespective of this, the
increase of UCP2 under these conditions does not in itself argue
that UCP2 protects against oxidative stress; it could equally well
be argued that it augments the stress [50].
Particularly the possibility that UCP2 is neuroprotective in
the brain has recently received much attention [51,52]. Again,
the mere observation that UCP2 gene expression levels are
increased under conditions of induced oxidative stress in the
brain cannot in itself be considered evidence that UCP2 is
protective, but there are two other types of observations that are
of a more functional nature.
One type results from artificial overexpression of UCP2 in
(areas) of the brain (e.g., [53–55]). Evidence is presented that
this is associated with decreased brain damage after experi-
mental ischemia of the brain and with decreased cell death in
cultured neurons [53]. It is generally accepted that when UCP2
is artificially overexpressed, it does lead to uncoupling, and
evidence is also presented that is interpreted to indicate that the
brain mitochondria are more uncoupled in the UCP2-over-
expressing mice. It was therefore hypothesized that the
neuroprotective action was secondary to “mild” uncoupling,
and indeed also a chemical uncoupler (DNP) could decrease cell
death in cultured neurons [53]. As it is doubtful that
endogenously expressed UCP2 is inherently uncoupling (see
above), the conclusion that can be made is the interesting one
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does not demonstrate that UCP2 has this effect when it is
endogenously expressed.
Here the results of studies with UCP2 KO mice are of
particular interest. Studies in UCP2 KO mice gave results that
are remarkably similar to those observed with UCP2 over-
expressing mice: also in the UCP2 KO mice, less damage was
observed following experimental ischemia in the brain [56].
However, with respect to UCP2 function, the interpretation of
these results must clearly be principally the opposite: UCP2 is
not protective. Although the reason for the reduced damage in
this study was indicated to be an increased glutathione level in
the UCP2 KO mice, the UCP2 KO data clearly do not support
an essential role – or even an auxillary positive role – of UCP2
in protection against oxidative damage. This is to our
knowledge the only paper directly investigating such a role;
all other reports are circumstantial, and this paper thus directly
contradicts a protective role of UCP2.
If UCP2 plays a significant role in the protection against
oxidative damage, and if oxidative damage is a major cause of
cancer and other pathological conditions, it could also be
expected that UCP2 KO mice should spontaneously present
with increased frequencies of different pathological conditions
and a reduced life span. No such study has as yet been
published, implying that such changes have not been evident in
UCP2 KO mouse colonies. This may indicate either that UCP2
is not a major defence against oxidative damage, or that
oxidative damage does not have the significance for develop-
ment of pathological states normally ascribed to it. However, a
recent article provides evidence that UCP2 KO mice develop
more tumours after treatment with a carcinogen than do wild-
type mice [57].
Functions of UCP2 not related to protection against ROS
have been proposed (reviewed in [2] with further suggestions in
[33,49,58,59]) but will not be discussed here.
2.3. Does UCP3 protect against oxidative damage?
Due to the possibility of neuroprotection by UCP2, the
possibility that UCP2 protects against oxidative damage has
gained much more interest than the possibility that UCP3 has
this function; skeletal muscle is not generally considered to be
as “critical” as nerves (although a protective role of UCP3 in
heart would clearly be of interest [73,74]). An early study of
UCP3 KO mice indicated marginal increases in several
measures of oxidative damage in muscle mitochondria [60]
but this is apparently the only study that has examined evidence
for this central issue. Studies of artificial UCP3 overexpression
which have indicated diminished ROS production may share
the problem with other UCP overexpression studies that the
procedure may lead to an inherent uncoupling associated with
the insertion of UCP3 that is apparently not observed with
endogenously expressed UCP3 (but notably, in one such study,
a diminished ROS production was seen without indications of
mitochondrial uncoupling [61], an observation that implies that
UCP3 affects ROS production in an unknown way). In the same
vein, GDP has been shown to accelerate “spontaneous”aconitase inactivation in normal muscle mitochondria (which
contain UCP3) but this effect is absent in mitochondria from
UCP3-KO mice [62]. These latter observations reflect oxidative
stress conditions in-vitro, and convincing evidence for substan-
tial in-vivo oxidative damage in muscle of UCP3 KO is
presently missing. Physiologically increased UCP3 levels in
human muscle does not seem to lead to accumulation of less 4-
hydroxy-2-nonenal /protein adducts [63].
2.4. Conclusion concerning the role of UCPs in protection
against oxidative damage
Despite much interest in the suggestion that UCPs have an
important role in the protection against oxidative damage,
convincing in-vivo data demonstrating this is not presently at
hand, and some data even indicate a detrimental effect of UCPs
under conditions of oxidative stress. If the suggested protective
effect is due to an induced UCP2-mediated mitochondrial
uncoupling, and in view of the fact that UCP2 and UCP3,
compared with UCP1, are present in very low amounts in the
mitochondrial membrane, it is presently not understandable
how they can catalyze a sufficiently high proton leak to allow
for the degree of uncoupling needed.
3. What controls the production of ROS?
The underlying premises in all discussions concerning the
possibility that UCPs act as protectors against oxidative damage
are that mitochondria, within cells, will reach high membrane
potentials and induce superoxide production and thus oxidative
damage, and that therefore a “mild uncoupling” (by UCPs, to
the extent they are capable of uncoupling) would dramatically
decrease oxidative damage.
However, each of these premises may be discussed.
Concerning the premise that mitochondria within cells will
reach high membrane potential, it may be pointed out that
normally, when metabolism is investigated in isolated cell
systems of any kind, the rate of oxygen consumption is
inhibitable by oligomycin. This indicates that even in
unstimulated cells, ATP synthesis is ongoing—and this in its
turn implies that the mitochondria are far from being in “state
4”, even in unstimulated cells. It may therefore be stated that it is
unlikely that mitochondria ever “need” a mechanism for partial
uncoupling because they will always physiologically be in a
state with a non-maximum membrane potential (as is always the
case when ATP is being synthesized).
The premise that a “mild” uncoupling is sufficient to
significantly decrease superoxide production is substantiated
by observations that, e.g., a 10 mV depolarization may lead to a
marked decrease in the rate of ROS production under
experimental conditions [64,65]. However, although 10 mV
may not seem much, a depolarization of this magnitude must
lead to substantial increases in the rate of oxygen consumption,
based on established Mitchellian control of respiratory chain
activity. This would mean that if “mild” uncoupling constantly
occurs due to the activity of UCPs in the body, all UCPs (not
only UCP1) must be thermogenic, and the ablation of a UCP
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is not the case [36].
The most controversial premise is related to the issue as to
whether a high mitochondrial membrane potential really leads
to a high rate of ROS production. Although standard literature
since the early 1970s has apparently agreed on this concept [66],
there are experimentalists who doubt this maxim (e.g., [67,68]).
It may even be theoretically argued that the conditions routinely
used to demonstrate these effects (normally succinate respira-
tion), may not reflect conditions occurring in-vivo, and very
high ROS production rates are actually seen after the further
addition of antimycin (which successively leads to decreased
membrane potential).
Indeed, accepted concepts concerning oxidative damage are
that it would occur when mitochondria produce superoxide in
high, concentrated amounts. This would occur under conditions
where the membrane potential is high, where there is no flux
through the respiratory chain, where there are ample amounts of
substrate for oxidation and where there is a high mitochondrial
density. Conversely, low risk for oxidative damage should occur
under conditions where the mitochondrial membrane potential
is low and where there is a high flux through the respiratory
chain. It may be pointed out that normal brown-fat mitochondria
in-situ, under stimulated conditions when heat production is
needed, should clearly represent a condition with a very low risk
of oxidative damage: UCP1 is constantly highly active,
resulting in a low membrane potential and a very high flux of
electrons through the respiratory chain. In contrast, the brown-
fat mitochondria in UCP1-ablated mice under the same
physiological conditions should be extremely prone to oxidative
damage: there is an abundant supply of substrate for oxidation,
the mitochondria are dense in the cell, the membrane potential is
as high as can be generated, and there is practically no electron
flux through the system, as protons are unable to re-enter the
mitochondrial matrix, either through UCP1 (that is removed), or
through the ATP-synthase (that has extremely low capacity in
brown-fat mitochondria [69,70]). Further, there is no evidence
for an enhanced activity of known antioxidative systems [14].
Thus, if two physiological states should result in dramatic
differences between oxidative damage, it should be these two,
and provided that brown adipose tissue is not endowed with an
unknown, specific, novel mechanism for protection against
ROS, brown-fat mitochondria isolated from these two condi-
tions should demonstrate large differences in the degree of
accumulated oxidative damage. However, no difference is seen
[14].
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